Pharma Industry News
PMN Home | Advertising Information | FAQs
About Us | Contact Us | Privacy Policy
Subscribe Glossary
Pharma Marketing Blog Pharmaguy Audio Podcasts Event Calendar PReader Surveys

Share |

Pharma Industry News Update: 7 April 2017 Previous Issue

Gottlieb's Views on Drug Safety Versus Speed to Market
In this 3.5-minute audio snippet, Pharmaguy summarizes the testimony of Dr. Scott Gottlieb, president Trump's nominee to head the FDA, before the U.S. Senate Committee on Health, Education, Labor and Pensions. In particular, where's the balance between drug safety and speeding up clinical trials to bring drugs to market faster?

Senator Warren Goes After Gottlieb Regarding Drug Safety


At his April 5, 2017, Senate confirmation hearing, Dr. Scott Gottlieb, President Trump's nominee for FDA Commissioner, responded to Massachusetts Senator Elizabeth Warren's concern about his commitment to FDA's basic safety mission.

Senator Warren cited Gottlieb's comments about how the thalidomide episode had a lasting effect on the FDA's work. The comments appeared in a 2012 article titled "Changing the FDA's Culture."

In that article, Gottlieb said "In so heavily prioritizing one of its obligations - the protection of consumers - the FDA has sometimes subordinated and neglected its other key obligation, which is to guide new medical innovations to market."

More here...

Further Reading & Listening:

Gottlieb Redefines What is Meant by "Gold Standard" at His Senate Hearing


When Dr. Scott Gottlieb pledged at his confirmation hearing to uphold a "gold standard of safety and efficacy" at the Food and Drug Administration, he raised an important question:

What exactly does he mean by that?

Traditionally, "gold standard" refers to robust, randomized controlled clinical trials. But there's enormous pressure on the FDA from pharma companies and Congress to accept other kinds of evidence, perhaps even patient anecdotes, to determine whether experimental drugs work. And President Trump is promising to speed drug approvals.

So when Gottlieb said: "I think there are ways to modernize clinical studies without sacrificing the gold standard," he raised red flags.

More here...

Further Reading:

Dr. Gottlieb's Comments on Opioid Epidemic

At his April 5, 2017, Senate confirmation hearing, Dr. Scott Gottlieb, President Trump's nominee for FDA Commissioner, answered questions about the opioid epidemic thrown at him by Senators Tim Kaine, Michael Bennet, and Al Franken.

Listen to Gottlieb's comments here.

Further Reading:

Pharma Industry News Update
Welcome to Pharma Industry News Update (aka PinUp), a publication of Pharma Marketing News. PinUp presents curated content of topical interest from a variety of sources.

Messages from Our Sponsors

Contact Information
Pharma Marketing News

Pharma Marketing News | Subscribe | Industry Insights | Podcasts | Pharmaguy | Blog
Surveys | Glossary | Conference Calendar | Advertising Information | FAQs | About Us | Privacy Policy

© 2017. Pharma Marketing Network. All rights reserved.